AzTrials
AzTrials

Living Donor Kidney TransplantationMuST AKTNCT04666545

Multidisciplinary Support To Access Living Donor Kidney Transplant-Pilot

A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

For patients with kidney failure the two treatment options are kidney transplantation or dialysis. Transplantation offers longer survival, better quality of life and provides cost savings for the health system (>$60,000/year per patient). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Living Donor Kidney Transplantation
What is being tested?
MuST AKT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
1 siteCanada
Study dates
12 May 2021to Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • English speaking
  • No obvious contraindication to kidney transplantation
  • Completed 'introduction to kidney transplant' module

Who cannot join

  • Potential Living Kidney Donor identified
  • Previously received organ transplant
  • Candidate for multi-organ transplant
  • Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Score > 20
  • Rapid Estimate of Adult Literacy in Medicine (REALM-66) score < 19 (illiterate in English)

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • University of Alberta Hospital

    Edmonton, Alberta

Other trials in Canada

About this study

Official title: Multidisciplinary Support To Access Living Donor Kidney Transplant (MuST AKT)- A Pilot Randomized Controlled Trial

For patients with kidney failure the two treatment options are kidney transplantation or dialysis. Transplantation offers longer survival, better quality of life and provides cost savings for the health system (>$60,000/year per patient). Unfortunately, there are not enough organs available and 20% of patients die on dialysis waiting for a deceased donor kidney.

Living kidney donation is a safe and proven treatment that leads to even better patient and health system outcomes than deceased donor kidney transplant. The Kidney Health Strategic Clinical Network (KH-SCN) identified increasing living kidney donation as a priority and in 2015 established the Living Donor Kidney Transplant Working Group (LDKTWG) comprised of patients, donors, health care professionals, researchers, and administrators. In an evidenced review published by the investigators, the intervention with the best evidence and greatest impact was personalized support provided by a multidisciplinary team to inform and educate the patients' social network. This intervention increased living kidney donations by 34%. The investigators confirmed through a province wide survey that many patients with kidney failure are unable to find a living kidney donor and find it difficult to approach potential donors due to lack of skills, supports, and resources and these issues are particularly apparent in vulnerable populations. The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support patients in identifying and communicating with their social networks. The investigators will test the effectiveness of this intervention.

Read the detailed description

Living donor kidney transplantation is the optimal treatment for end-stage kidney disease patients, dramatically improving survival and quality of life, providing significant cost saving compared with dialysis, reducing the demand for deceased donor transplants and the pressure to increase dialysis capacity and infrastructure. Outcome data shows that only 16% of Canadians on dialysis survive past 10 years, whereas up to 74% of Canadians with a kidney transplant have a functioning kidney after 10 years. The ideal treatment trajectory is to avoid dialysis entirely and receive a living donor transplant prior to dialysis (pre-emptive), which unfortunately only occurs in 10.5% of eligible patients.

Patients with end-stage kidney disease report being overwhelmed with other issues (loss of work, family stress, fear of dialysis) and lack the skills needed to comfortably engage potential living donors - many feel uncomfortable doing so and do not know how to start. The purpose of this research is to test an intervention designed to support patients identification of potential donors and communication with their social network and ultimately increase the number of living donor kidney transplantations.

Justification:

The rate of living kidney donor transplantation is lower in Alberta compared to other provinces in Canada. As the rate of kidney failure has increased over the past few years in Alberta, it is necessary to improve and facilitate the process of living kidney donor transplantation for better patient care.

Primary Objective:

The primary objective of this study is to examine the efficacy of the MuST AKT program to facilitate patients' identification of potential living kidney donors compared to usual care.

Hypothesis:

The investigators hypothesize that the MuST AKT program will increase the proportion of participants with at least one potential living kidney donors who started evaluation (intervention vs control).

Additional Objectives:

The secondary objective is to evaluate patient outcome improvement by collecting Patient Reported Outcome Measures (PROMs) to assess the proportion of patients who find at least one potential living donor.

The tertiary objective is to evaluate patient experience by collecting Patient Reported Experience Measures (PREMs) to determine whether participants recommend this program to other patients and to what extent this program gave them confidence for finding a potential living kidney donor.

The quaternary objective is to evaluate the feasibility of this program by assessing consent rate, attendance, adherence, and drop-out.

Research Methods/Procedures:

This is a pilot parallel randomized controlled trial with a qualitative interview component. The intervention condition will receive a multidisciplinary, tailored person-centered intervention over three months (MuST AKT program), and the control condition will receive the current standard of care (social worker assessment).

Patients who have been referred for kidney transplantation assessment in Edmonton will be contacted during a standard care kidney transplant education session or over the telephone if patients have completed the transplant education and are on the deceased kidney donor wait-list. Patients who expressed interest will be contacted via telephone by a member of the research team to seek their consent, complete the initial screening assessment to confirm their eligibility and enrolment, and then complete a baseline questionnaire. Then participants will be randomized to either the intervention or control condition, using predetermined randomly-generated (by Stata MP 15·1) permuted blocks of 4 and 6. Assignment to condition will be concealed by the database up until the point of assignment. Participants in the intervention condition will receive the MuST AKT program and participants in the control condition will receive usual care. Consent rate, attendance, adherence, and drop-out will be tracked during enrollment and the duration of the intervention. Upon completion of the intervention (or usual care), participants will complete a post-intervention questionnaire to assess PREMs. Participants in the intervention condition will be contacted after they have completed the post-questionnaire to participate in a qualitative interview lasting approximately 40 minutes. Kidney transplant status will be tracked for a period of 24 months post-intervention. Participants in the intervention condition who do not have a potential donor come forward after 12 months will be contacted to complete an additional interview to explore factors contributing to their lack of success, which will last approximately 40 minutes.

Intervention Condition: MuST AKT is a multidisciplinary, tailored person-centered intervention aimed to support participants identification of potential donors and communication with their social network. A one-on-one introductory session will be followed by three 'one-on-one' sessions (A, B and C) and a final session D with participants family and friends (potential donors and advocates) identified in session A. All group and individual sessions will be arranged virtually during the COVID-19 pandemic, and may be held either virtually or in-person, at the participants discretion, in the event that the COVID-19 pandemic concludes and physical distancing requirements have been eliminated. Each education session will take approximately 90 minutes. Sessions will be facilitated by a trained licensed social worker, coordinator or social media expert with extra training in kidney disease, transplantation, living kidney donation, counselling and interviewing, and patient confidentiality.

Usual care (control condition): In the control condition, participants will go through the current standard of care, which is a social worker assessment. If the intervention is successful in the definitive RCT (to be conducted later) and approved by Alberta Health Services as the 'new standard of care', people in control condition will be contacted and given the option to participate in the MuST AKT program.

Additional interviews with separate informed consent procedures:

(Patients) If, during recruitment for the study, the individual indicates they do not want to participate, or if participants drop-out of the study, a research team member will invite them participate in a 20-40 minute interview to understand barriers to participation in the study.

(Friends and family of patients) Friends and family members of participants who take part in session D will be invited to participate in an interview approximately 40 minutes long which aims to explore their experiences of group session D.

Plan for Data Analysis - Quantitative:

All analyses will be completed in Stata/MP 17.0 (www.stata.com), using an intention-to-treat approach. The investigators will use the Fisher's exact tests (dichotomous outcomes) and t-tests or Wilcoxon rank-sum tests (continuous outcomes data), as appropriate.

Our primary analyses (of our primary and secondary outcomes #1-4) will pool data from both the current and the definitive trials. In secondary analyses, the investigators will generate within trial results to investigate potential heterogeneity of intervention delivery.

Plan for Data Analysis - Qualitative Telephone interviews will be conducted using semi-structured interview guides. Data will be analyzed using a thematic analysis approach, whereby common themes that emerge from the data are documented. The qualitative software NVivo-12 will be used in the analysis.

Being tested
MuST AKT

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MuST AKTBehavioural

    A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.

Study groups in NCT04666545
Study groupRoleWhat they receive
InterventionExperimentalThis arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation.
Receives: Behavioral: MuST AKT
Usual Care (control)No interventionIn the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Living Kidney Donor Evaluation Started

    Proportion of participants with at least one potential donor who started evaluation

    Measured: 12 months

Secondary outcomes (4)
  1. Living Kidney Donor Transplantation

    Proportion of living kidney donor transplantations

    Measured: 24 months

  2. Contact Living Donor Services

    Proportion of participants with at least one potential donor who contacted living donor services

    Measured: 12 months

  3. Living Kidney Donor Evaluation Completed

    Proportion of participants with at least one potential donor who completed evaluation

    Measured: 12 months

  4. Identified potential advocates

    Number of participants who found at least one potential advocate

    Measured: From date of first to last documented session, an average of 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Dec 2020
  2. Study start12 May 2021
  3. Primary completionSep 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Pilot parallel block randomized controlled trial
Masking
Single blind
Who is masked
Investigator
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04666545
Sponsor's protocol ID
Pro00097902
Acronym
MuST AKT
Status last verified
Jan 2026
First submitted
23 Nov 2020
Last updated
7 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Vandermeer B, Corradetti B, Dhaliwal A, Ferdinand S, Ikekekpolor D, Smith G, Bello AK, Wen K, Shojai S. The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial. Transpl Int. 2026 Feb 25;39:15472. doi: 10.3389/ti.2026.15472. eCollection 2026.

    PubMed 41822027
  • Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, Wiebe N, Corradetti B, Ferdinand S, Iyekekpolor D, Smith G, Verdin N, Bello AK, Wen K, Shojai S; Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) Research Group. Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT): A Clinical Research Protocol for a Pilot Randomized Controlled Trial to Increase Living Kidney Donation. Can J Kidney Health Dis. 2023 Oct 30;10:20543581231205340. doi: 10.1177/20543581231205340. eCollection 2023.

    PubMed 37920779

Questions about this trial

What is this clinical trial studying?

A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Living Kidney Donor Evaluation Started (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04666545, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in